With increasing knowledge of clinical in vivo biomarkers and the pathological intricacies of
Alzheimer's disease (AD), nosology is evolving. Harmonized consensus criteria that …

Alzheimer's disease (AD) dementia is one of the most common types of dementia in older
adults. As the population ages, the number of patients who are concerned about cognitive …

Objective While many studies suggest that patients with Alzheimer's disease have a higher
chance for developing epileptic seizures, only a few studies are available examining …

Alzheimer's disease (AD), the most common type of dementia, is a severe
neurodegenerative disorder. Identifying biomarkers that can track the progress of the …

The Alzheimer's Disease Prediction Of Longitudinal Evolution (TADPOLE) Challenge
compares the performance of algorithms at predicting future evolution of individuals at risk of …

There have been magnificent advancements in the understanding of molecular mechanisms
of chronic diseases over the past several years, but these diseases continue to be a …

Early stages of many neurodegenerative diseases, such as Alzheimer's disease, vascular
and frontotemporal dementia, and Parkinson's disease, are frequently associated with Mild …

Acetylcholinesterase inhibitors (ChEI) are the global standard of care for the symptomatic
treatment of Alzheimer's disease (AD) and show significant positive effects in …

Background Whether age at onset influences Alzheimer's disease (AD) progression and the
effectiveness of cholinesterase inhibitor (ChEI) therapy is not clear. We aimed to compare …

Moderate-to-severe traumatic brain injury is one of the strongest environmental risk factors
for the development of neurodegenerative diseases such as late-onset Alzheimer's disease …